GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Cyclically Adjusted Revenue per Share

TECH (Bio-Techne) Cyclically Adjusted Revenue per Share : $0.00 (As of Mar. 2025)


View and export this data going back to 1992. Start your Free Trial

What is Bio-Techne Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bio-Techne's adjusted revenue per share for the three months ended in Mar. 2025 was $1.989. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Bio-Techne's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bio-Techne was 15.80% per year. The lowest was 8.60% per year. And the median was 11.60% per year.

As of today (2025-05-11), Bio-Techne's current stock price is $49.94. Bio-Techne's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $0.00. Bio-Techne's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 7.95. And the median was 14.13.


Bio-Techne Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Bio-Techne's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Cyclically Adjusted Revenue per Share Chart

Bio-Techne Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.43 3.96 4.75 5.33 5.89

Bio-Techne Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.75 5.89 6.00 6.09 -

Competitive Comparison of Bio-Techne's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted PS Ratio falls into.


;
;

Bio-Techne Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Techne's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.989/134.9266*134.9266
=1.989

Current CPI (Mar. 2025) = 134.9266.

Bio-Techne Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.789 100.684 1.057
201509 0.753 100.392 1.012
201512 0.810 99.792 1.095
201603 0.878 100.470 1.179
201606 0.901 101.688 1.196
201609 0.871 101.861 1.154
201612 0.879 101.863 1.164
201703 0.960 102.862 1.259
201706 1.043 103.349 1.362
201709 0.959 104.136 1.243
201712 1.016 104.011 1.318
201803 1.075 105.290 1.378
201806 1.173 106.317 1.489
201809 1.050 106.507 1.330
201812 1.126 105.998 1.433
201903 1.189 107.251 1.496
201906 1.225 108.070 1.529
201909 1.167 108.329 1.454
201912 1.169 108.420 1.455
202003 1.234 108.902 1.529
202006 1.112 108.767 1.379
202009 1.275 109.815 1.567
202012 1.393 109.897 1.710
202103 1.497 111.754 1.807
202106 1.579 114.631 1.859
202109 1.565 115.734 1.825
202112 1.634 117.630 1.874
202203 1.772 121.301 1.971
202206 1.762 125.017 1.902
202209 1.663 125.227 1.792
202212 1.679 125.222 1.809
202303 1.820 127.348 1.928
202306 1.859 128.729 1.949
202309 1.710 129.860 1.777
202312 1.703 129.419 1.775
202403 1.891 131.776 1.936
202406 1.905 132.554 1.939
202409 1.797 133.029 1.823
202412 1.849 133.157 1.874
202503 1.989 134.927 1.989

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Bio-Techne  (NAS:TECH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 7.95. And the median was 14.13.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bio-Techne Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Executives
Kim Kelderman officer: Pres. Diagnostics & Genom 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Robert V Baumgartner director 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Roeland Nusse director 473 TENNESSEE, PALO ALTO CA 94306
William Geist officer: PRESIDENT, PROTEIN SCIENCES 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth director, officer: Chief Executive Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor officer: SVP Biotech 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel officer: Chief Financial Officer 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan director C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Julie L Bushman director 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Randolph C Steer director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413